NewsRelease

Cleanascite™Cited in Study of Metabolic Dysfunction–associated Steatotic LiverDisease

MONMOUTHJUNCTION, NJ, December9, 2024 -- Biotech Support Group reports on an article, describingthe simplicity and efficiency of their lipid clearance samplepreparation from plasma for mass spectrometry measurement of intactinsulin and C-peptide. Thecitation is: 

HuneaultHE, Lo JS, Bai S, He Z, McPhaul MJ, Bril F, et al. Fastingintact insulin by mass spectrometry is associated with metabolicdysfunction-associated steatotic liver disease in youth.Hepatol Commun. 2024;8: e0582. https://doi.org/10.1097/HC9.0000000000000582

Metabolicdysfunction–associated steatotic liver disease (MASLD), formerlyknown as NAFLD, is the most common liver disease in children and is aleading cause of liver-related morbidity and mortality. Fastingintact insulin concentrations can predict metabolicdysfunction–associated steatotic liver disease (MASLD) in adultswithout diabetes; however, research in youth is limited. This studysought to determine whether fasting intact insulin, measured byliquid chromatography-tandem mass spectrometry, is associated withMASLD in children. The methods describe “Quest Diagnostics NicholsInstitute performed measurements of intact insulin and C-peptide…the samples were plated and mixed with the addition of internalstandards (bovine insulin and a stable isotopically labeled [13C/15N]C-peptide) and Cleanascite delipidation reagent.” The studyindicates that similar to adults, measures of fasting intact insulinalone and in combination with ALT (intact insulin × ALT) arestrongly associated with MASLD in children and adolescents. Thefindings offer promising support for the use of fasting intactinsulin and ALT levels as a simple, noninvasive method for diagnosingMASLD in pediatric patients. 

“Iam pleased to see another reference highlighting Cleanascite™ useto help remove lipids from plasma, as part of the sample prepworkflow in mass spectrometry analysis.” states Swapan Roy, Ph.D.,President and Founder of Biotech Support Group.

Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords:Lipiddepletion, Cleanascite™, Metabolicdysfunction–associated steatotic liver disease (MASLD), intactinsulin, C-peptide

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. Forthis market, key products include: AlbuVoid™ and AlbuSorb™ PLUSforalbumin & IgG depletion, Cleanascite™for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobinremoval, and NRicher™ for targeted proteomics and family specificproteome enrichment.For more information, go tohttp://www.biotechsupportgroup.com.

ForBusiness Development,contact:MatthewKuruc 732-274-2866, [email protected]